Literature DB >> 23380730

Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.

Helio S Sader1, Robert K Flamm, Ronald N Jones.   

Abstract

Ceftaroline-avibactam and comparator agents were tested by the broth microdilution method against 20,089 isolates consecutively collected in 2010 and 2011 from 75 U.S. medical centers. Ceftaroline-avibactam was active against Enterobacteriaceae (4,908 strains; MIC90, 0.25 μg/ml; highest MIC, 4 μg/ml), including meropenem-nonsusceptible Klebsiella spp. and ceftazidime-nonsusceptible Enterobacter cloacae strains (MIC90, 1 μg/ml for both). Ceftaroline-avibactam was also active against ceftriaxone-nonsusceptible Streptococcus pneumoniae (MIC(90), 0.25 μg/ml) and methicillin-resistant Staphylococcus aureus (MIC(90), 1 μg/ml).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23380730      PMCID： PMC3623348          DOI： 10.1128/AAC.02436-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

Authors:  S Mushtaq; M Warner; G Williams; I Critchley; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-05-17       Impact factor: 5.790

2.  Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).

Authors:  Mariana Castanheira; Rodrigo E Mendes; Leah N Woosley; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2011-03-18       Impact factor: 5.790

Review 3.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

4.  Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

5.  Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.

Authors:  Mariana Castanheira; Helio S Sader; David J Farrell; Rodrigo E Mendes; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

6.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

Review 7.  Summary of ceftaroline fosamil clinical trial studies and clinical safety.

Authors:  Thomas M File; Mark H Wilcox; Gary E Stein
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079
  7 in total
  16 in total

Review 1.  [New antibiotics prior to approval: is this the end of the innovative stagnation?].

Authors:  J R Bogner
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

2.  Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.

Authors:  I J Abbott; A W J Jenney; C J Jeremiah; M Mirčeta; J P Kandiah; D C Holt; S Y C Tong; D W Spelman
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 4.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

5.  Ceftaroline-Fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model.

Authors:  Laure Gatin; Azzam Saleh-Mghir; Jason Tasse; Idir Ghout; Frédéric Laurent; Anne-Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

6.  In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors:  Henry Li; Mark Estabrook; George A Jacoby; Wright W Nichols; Raymond T Testa; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.

Authors:  Yunliang Zhang; Ankita Kashikar; C Adam Brown; Gerald Denys; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model.

Authors:  Amira A Bhalodi; Jared L Crandon; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

10.  In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.

Authors:  Xiaojuan Wang; Feifei Zhang; Chunjiang Zhao; Zhanwei Wang; Wright W Nichols; Raymond Testa; Henan Li; Hongbin Chen; Wenqiang He; Qi Wang; Hui Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.